SG11201804601TA - Methods for preparing substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine - Google Patents

Methods for preparing substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine

Info

Publication number
SG11201804601TA
SG11201804601TA SG11201804601TA SG11201804601TA SG11201804601TA SG 11201804601T A SG11201804601T A SG 11201804601TA SG 11201804601T A SG11201804601T A SG 11201804601TA SG 11201804601T A SG11201804601T A SG 11201804601TA SG 11201804601T A SG11201804601T A SG 11201804601TA
Authority
SG
Singapore
Prior art keywords
international
pct
methods
rule
publication
Prior art date
Application number
SG11201804601TA
Other languages
English (en)
Inventor
Craig Bates
David P Reed
Jianmin Mao
Original Assignee
Arqule Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arqule Inc filed Critical Arqule Inc
Publication of SG11201804601TA publication Critical patent/SG11201804601TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SG11201804601TA 2015-12-17 2016-12-16 Methods for preparing substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine SG11201804601TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562268758P 2015-12-17 2015-12-17
PCT/US2016/067161 WO2017106639A1 (en) 2015-12-17 2016-12-16 Methods for preparing substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine

Publications (1)

Publication Number Publication Date
SG11201804601TA true SG11201804601TA (en) 2018-07-30

Family

ID=59057623

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201804601TA SG11201804601TA (en) 2015-12-17 2016-12-16 Methods for preparing substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine

Country Status (16)

Country Link
US (4) US9834519B2 (cg-RX-API-DMAC7.html)
EP (2) EP4015508A1 (cg-RX-API-DMAC7.html)
JP (2) JP6940504B2 (cg-RX-API-DMAC7.html)
KR (1) KR20180085814A (cg-RX-API-DMAC7.html)
CN (2) CN114874149A (cg-RX-API-DMAC7.html)
AU (2) AU2016369520B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018012325A2 (cg-RX-API-DMAC7.html)
CA (1) CA3006077A1 (cg-RX-API-DMAC7.html)
EA (1) EA201891431A1 (cg-RX-API-DMAC7.html)
HK (1) HK1255014A1 (cg-RX-API-DMAC7.html)
IL (1) IL259557A (cg-RX-API-DMAC7.html)
MX (2) MX2020012771A (cg-RX-API-DMAC7.html)
NZ (1) NZ742785A (cg-RX-API-DMAC7.html)
SG (1) SG11201804601TA (cg-RX-API-DMAC7.html)
TW (1) TWI748972B (cg-RX-API-DMAC7.html)
WO (1) WO2017106639A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017106642A1 (en) 2015-12-17 2017-06-22 Arqule, Inc. Solid forms of substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds
MX2020012771A (es) 2015-12-17 2022-10-04 Arqule Inc Metodos para preparar 5,6-dihidro-6-fenilbenzo[f]isoquinolin-2-ami na sustituida.
CN110669015A (zh) * 2018-07-03 2020-01-10 上海喀露蓝科技有限公司 一种fgfr抑制剂的制备方法
US10878412B2 (en) * 2019-05-13 2020-12-29 Truist Bank In-line verification of transactions
WO2022053708A1 (en) 2020-09-14 2022-03-17 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of gastric adenocarcinoma

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
AU5330698A (en) * 1996-12-23 1998-07-17 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
GB9713087D0 (en) * 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
AU2005316312B2 (en) * 2004-12-17 2009-10-22 Amgen, Inc. Aminopyrimidine compounds and methods of use
CA2710051C (en) 2006-12-29 2017-05-16 Rigel Pharmaceuticals, Inc. Substituted triazoles useful as axl inhibitors
GB2449293A (en) * 2007-05-17 2008-11-19 Evotec Compounds having Hsp90 inhibitory activity
CN102325755B (zh) * 2008-12-30 2015-07-01 艾科尔公司 取代的5,6-二氢-6-苯基苯并[f]异喹啉-2-胺化合物
JP5808818B2 (ja) 2010-11-25 2015-11-10 ラツィオファーム・ゲーエムベーハー アファチニブの新規塩及び多形形態
WO2012177852A1 (en) * 2011-06-24 2012-12-27 Arqule, Inc Substituted imidazopyridinyl compounds
WO2015150900A2 (en) * 2014-03-31 2015-10-08 Debiopharm International Sa Fgfr fusions
WO2017106642A1 (en) 2015-12-17 2017-06-22 Arqule, Inc. Solid forms of substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds
MX2020012771A (es) * 2015-12-17 2022-10-04 Arqule Inc Metodos para preparar 5,6-dihidro-6-fenilbenzo[f]isoquinolin-2-ami na sustituida.

Also Published As

Publication number Publication date
CA3006077A1 (en) 2017-06-22
AU2021202610B2 (en) 2022-06-02
JP6940504B2 (ja) 2021-09-29
US20190241527A1 (en) 2019-08-08
US9834519B2 (en) 2017-12-05
AU2021202610A1 (en) 2021-05-27
HK1255014A1 (zh) 2019-08-02
EP4015508A1 (en) 2022-06-22
WO2017106639A1 (en) 2017-06-22
JP2021191782A (ja) 2021-12-16
EP3390368A4 (en) 2019-07-03
US20180065937A1 (en) 2018-03-08
CN114874149A (zh) 2022-08-09
MX385672B (es) 2025-03-18
MX2018007415A (es) 2018-11-09
JP2018537495A (ja) 2018-12-20
KR20180085814A (ko) 2018-07-27
US10093632B2 (en) 2018-10-09
EA201891431A1 (ru) 2018-11-30
CN108602779A (zh) 2018-09-28
IL259557A (en) 2018-07-31
US20170174637A1 (en) 2017-06-22
AU2016369520A1 (en) 2018-06-07
MX2020012771A (es) 2022-10-04
BR112018012325A2 (pt) 2018-12-04
NZ742785A (en) 2023-06-30
TWI748972B (zh) 2021-12-11
EP3390368A1 (en) 2018-10-24
US11279679B2 (en) 2022-03-22
TW201733992A (zh) 2017-10-01
AU2016369520B2 (en) 2021-02-18
US10766868B2 (en) 2020-09-08
US20200102276A1 (en) 2020-04-02

Similar Documents

Publication Publication Date Title
SG11201811491YA (en) Quinazoline and indole compounds to treat medical disorders
SG11201804132UA (en) Eif4-a-inhibiting compounds and methods related thereto
SG11201907356SA (en) Piperidine-substituted mnk inhibitors and methods related thereto
SG11201909949XA (en) Targeted immunotolerance
SG11201907840RA (en) Fused imidazo-piperidine jak inhibitors
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201908604YA (en) Fused imidazo-piperidine jak inhibitor compound
SG11201907434RA (en) Compositions and methods for immunooncology
SG11201810579YA (en) Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201804758QA (en) Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab
SG11201907023UA (en) Method of reducing neutropenia
SG11201810983PA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201804373VA (en) Compositions and methods for immunooncology
SG11201804856VA (en) C-terminal lysine conjugated immunoglobulins
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201903287PA (en) Anti-respiratory syncytial virus antibodies, and methods of their generation and use
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201810143PA (en) Exon skipping oligomers for muscular dystrophy
SG11201408251SA (en) A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota
SG11201901251SA (en) Aminopyrimidines as alk inhibitors
SG11201909376TA (en) Crystalline forms of a jak inhibitor compound
SG11201909807TA (en) Methods of manufacturing of niraparib
SG11201807949WA (en) Engineered immunoglobulins with altered fcrn binding